Emergent BioSolutions Files Proxy Materials

TL;DR

Emergent BioSolutions filed proxy docs, no fee. Standard corporate stuff.

AI Summary

Emergent BioSolutions Inc. filed a Definitive Additional Materials proxy statement on April 11, 2024. This filing is related to the company's proxy materials and indicates that no fee was required for this submission. The company is based in Gaithersburg, MD, and operates in the pharmaceutical preparations industry.

Why It Matters

This filing is a routine regulatory submission for Emergent BioSolutions, providing updated proxy information to shareholders. It does not contain new strategic announcements but is a necessary step in corporate governance.

Risk Assessment

Risk Level: low — This filing is a routine proxy statement update and does not contain new material information that would immediately impact the company's risk profile.

Key Players & Entities

• Emergent BioSolutions Inc. (company) — Registrant
• 20240411 (date) — Filing Date
• Gaithersburg, MD (location) — Company Address
• 240-631-3200 (phone_number) — Company Phone

FAQ

Filing Documents

• d173394ddefa14a.htm (DEFA14A) — 11KB
• g173394g04g04.jpg (GRAPHIC) — 262KB
• g173394g05g05.jpg (GRAPHIC) — 203KB
• 0001193125-24-093404.txt ( ) — 653KB

From the Filing

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the RegistrantFiled by a party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 Emergent BioSolutions Inc. (Name of Registrant as Specified in its Charter) Not applicable. (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. Your Vote Counts! EMERGENT BIOSOLUTIONS INC. 2024 Annual Meeting Vote by May 22, 2024 11:59 PM ET EMERGENT BIOSOLUTIONS INC. 300 PROFESSIONAL DRIVE GAITHERSBURG, MD 20879 V45248-P06298 You invested in EMERGENT BIOSOLUTIONS INC. and its time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the stockholder meeting to be held on May 23, 2024. Get informed before you vote View the Notice of the Meeting, Annual Report on Form 10-K, Proxy Statement and Proxy Card online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 9, 2024. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* May 23, 2024 9:00 a.m. Eastern Time Virtually at: www.virtualshareholdermeeting.com/EBS2024 *Please check the meeting materials for any special requirements for meeting attendance. Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Voting Items Board Recommends 1. To elect three Class III directors to hold office for a term expiring at our 2027 Annual Meeting of Stockholders, each to serve and until their respective successors are duly elected and qualified; Nominees Class III: 1a. Donald DeGolyer 1b. Neal Fowler 1c. Marvin White 2. To ratify the appointment by the audit and finance committee of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; 3. To hold, on an advisory basis, a vote to approve the 2023 compensation of our named executive officers; 4. To approve an amendment to the Emergent BioSolutions Inc. Amended and Restated Stock Incentive Plan. Other business may be considered as may properly come before the meeting or any adjournment or postponement of the meeting. For For For For For For Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click Delivery Settings. V45249-P06298

View Full Filing

View this DEFA14A filing on SEC EDGAR